Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Gastrointestinal Adverse Effects in Advanced Colorectal Carcinoma Patients Treated with Different Schedules of FOLFOX

  • Bano, Nusrat (Pharmacology Department, Ziauddin University) ;
  • Najam, Rahila (Pharmacology Department, University of Karachi) ;
  • Qazi, Faaiza (Jinnah University for Women) ;
  • Mateen, Ahmed (Radiotherapy Department, Karachi Institute of Radiotherapy and Nuclear Medicine)
  • Published : 2014.10.23
Download PDF
⟨ Previous Next ⟩

Abstract

Background: To assess the frequency and severity of gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with four different schedules of FOLFOX. Materials and Methods: Patients (median age 61 years) who underwent surgery were included in the study. All had measureable disease at CT scan, ultrasonography or clinical examination. Toxicity was graded on a scale of 1-5 according to the general grade definition of CTC v2.0. The severity of adverse effects (Grade 3 and 4) assessed in each treatment arm was compared. Results: Differences between the incidence rates of 3 and 4 toxicity and all grades of toxicity for all parameters in GI toxicity were very highly significant (p<0.001). Severe gastrointestinal symptoms of toxicity were noted with FOLFOX7 (oxaliplatin $130mg/m^2$). Grade 3 diarrhea was reported in 25% patients and grade 4 diarrhea in 4% in the FOLFOX7 treatment arm. Grade 2 vomiting was very frequently reported in the FOLFOX4 treatment arm (oxaliplatin $85mg/m^2$). Grade 2 stomatitis was reported in 42% patients treated with mFOLFOX6 (oxaliplatin $100mg/m^2$). Differences in the incidence rate of nausea, diarrhea and stomatitis among all treatment arms of FOLFOX were significant (p<0.05). Conclusions: Severe diarrhea is associated with FOLFOX7 treatment. No grade 3 or 4 GI toxicity was reported in patients of the mFOLFOX6 arm.

Keywords

References

  1. Bano N, Najam R, Mateen A (2013a). Neurological adverse effects in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX. Chemother Res Pract, 2013, 379870.
  2. Bano N, Najam R (2013b). Oxaliplatin: Its use in advanced colorectal carcinoma. Chem Inform, 44.
  3. Bano N, Najam R, Mateen A, Mirza T (2013c). Effects on cardiac biomarkers in colorectal cancer patients treated with FOLFOX. Pak J Med Dent, 2, 9-15.
  4. Bano N, Rahila N, Mateen A (2013d). Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX. Asian Pac J Cancer Prev, 14, 1781-86. https://doi.org/10.7314/APJCP.2013.14.3.1781
  5. Carlotto A, Hogsett VL, Maiorini EM, Razulis JG, Sonis ST (2013). The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. PharmacoEconomics, 31, 753-66. https://doi.org/10.1007/s40273-013-0081-2
  6. Comeau JM, Mohundro BL (2013). From bench to bedside: Promising colon cancer clinical trials. Am J Manag Care, 19, 32-7.
  7. Dogan K, Oztop I, Yavuzsen T, Ellidokuz H, and Yilmaz H (2011). Evaluation of the efficacy of modified De Gramont and modified FOLFOX4 regimens for adjuvant therapy of locally advanced rectal cancer. Asian Pac J Cancer Prev, 12, 3181-86.
  8. Gibson RJ, Keefe DMK, Lalla RV, et al (2013). Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer, 21, 313-26. https://doi.org/10.1007/s00520-012-1644-z
  9. Halit K, Deniz K, Berk V, Inanc M, Ozkan M (2012). Association of human epidermal growth factor receptor-2 expression and clinicopathological findings in patients with colorectal cancer. Asian Pac J Cancer Prev, 13, 6221-25. https://doi.org/10.7314/APJCP.2012.13.12.6221
  10. Joanne C, Tang V, Leung R, et al (2013). Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. Asian Pac J Cancer Prev, 14, 6585-90. https://doi.org/10.7314/APJCP.2013.14.11.6585
  11. Kuebler JP, Wieand HS, O'Connell MJ, et al (2007). Oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP protocol C-07. J Clin Oncol, 25, 2198-204. https://doi.org/10.1200/JCO.2006.08.2974
  12. Lee HJ, Kim HS, Park NH, et al (2013). Feasibility of oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-4) chemotherapy in heavily pretreated patients with recurrent epithelial ovarian cancer. Cancer Res Treat, 45, 40-7. https://doi.org/10.4143/crt.2013.45.1.40
  13. Najam R, Bano N, Mateen A (2013). Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma. Pak J Pharm Sci, 26, 1013-22.
  14. Nakatsumi H, Komatsu Y, Yuki S, et al (2013). Optimal dose period for indisetron tablets for preventing chemotherapyinduced nausea and vomiting with modified FOLFOX6: A randomized pilot study. Chemother, 58, 439-44.
  15. Qi C, Xia HW, Ge XJ, et al (2013). Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev, 14, 7421-26. https://doi.org/10.7314/APJCP.2013.14.12.7421
  16. Ramanathan RK, Clark JW, Kemeny NE, et al (2003). Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol, 21, 2904-11. https://doi.org/10.1200/JCO.2003.11.045
  17. Schultheis B, Folprecht G, Kuhlmann J, et al (2013). Regorafenib in combination with FOLFOX or FOLFIRI as first-or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol, 24, 1560-67. https://doi.org/10.1093/annonc/mdt056
  18. Sharif S, O'Connell MJ, Yothers G, Lopa S, Wolmark N (2008). FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest, 26, 956-63. https://doi.org/10.1080/07357900802132550
  19. Uncu D, Aksoy S, Cetin B, et al (2013). Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: Retrospective analysis of 667 patients. Oncol, 84, 240-5. https://doi.org/10.1159/000336902

Cited by

  1. Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update vol.21, pp.41, 2015, https://doi.org/10.3748/wjg.v21.i41.11793
  2. Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.1637
  3. Lactobacillus casei Variety rhamnosus Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model vol.9, pp.1664-302X, 2018, https://doi.org/10.3389/fmicb.2018.00983
  4. Chemotherapy protocols and incidence of oral mucositis. An integrative review vol.16, pp.1, 2018, https://doi.org/10.1590/s1679-45082018rw4007